VC: Gemin X leads with $65M second round

By admin Jun 1, 2005 8:01pm

Gemin X leads with $65M second round.

VENTURE CAPITAL
COMPANY	AMOUNT/ROUND	LEAD INVESTORS	DESCRIPTION
Gemin X Montreal	$65.2M second round	H.I.G., Sanderling	Funding will support Gemin X's continued clinical development of lead product candidate GX15-070, including an ongoing Phase I/II trial in patients with chronic lymphocytic leukemia and a Phase I trial in patients with solid tumors.
Oxagen Abingdon, UK	$59.8M second round	MPM Capital	The funds will advance Oxagen's small molecule anti-inflammatory for asthma to the clinic and expand the company's clinical and pre-clinical stage portfolio.
Phenomix San Diego	$40M second round	JPMorgan Partners, Delphi Ventures	The money will allow Phenomix to steer its lead drug into human trials.
Cylene Pharmaceuticals San Diego	$26.3M second round	Coastview Capital	The funding will allow Cylene to advance CX-3543, its lead product for the treatment of multiple cancers, into clinical development.
Aperon Biosystems Palo Alto, CA	$15.3M second round	Canaan Partners	Aperon is developing an in-home monitor for daily measurement of exhaled nitric oxide for the management of asthma.
Innovative Biosensors College Park, MD	$3.5M first round	Harbert Venture Partners	Innovative Biosensors is developing technologies for the rapid detection of pathogens.